| Little Rivers Health Care | |
|
4628 Main St S Newbury VT 05051-9712 | |
| (802) 866-3000 | |
| (802) 222-5674 |
| Full Name | Little Rivers Health Care |
|---|---|
| Speciality | Clinic/Center |
| Location | 4628 Main St S, Newbury, Vermont |
| Authorized Official Name and Position | Andrew Barter (PRESIDENT/CEO) |
| Authorized Official Contact | 8022224637 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Little Rivers Health Care Po Box 8 Newbury VT 05051-0008 Ph: (802) 866-3000 | Little Rivers Health Care 4628 Main St S Newbury VT 05051-9712 Ph: (802) 866-3000 |
| NPI Number | 1376119966 |
|---|---|
| Provider Enumeration Date | 06/03/2021 |
| Last Update Date | 05/24/2023 |
| Medicare PECOS PAC ID | 8224031497 |
|---|---|
| Medicare Enrollment ID | O20220106002752 |
News Archive
Ethicon Endo-Surgery, Inc. (EES), a Johnson & Johnson company, today announced it has received an irrevocable, unconditional offer from Devicor Medical Products (Devicor), a portfolio company of GTCR Golder Rauner, LLC, (GTCR), to acquire its Breast Care business. The EES Breast Care business sells products designed to help doctors diagnose breast cancer at early stages, while minimizing patient discomfort. Financial terms of the offer are not being disclosed.
The University of Florida will receive $29.5 million in federal stimulus funds over the next two years from the National Institute on Aging to begin a six-year study on whether a program of structured physical activity can prevent or delay major movement disability in older adults.
ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.
Bloomberg: "The government's cancer research network is 'approaching a state of crisis' as waste and inefficiency cause 40 percent of late-stage trials it funds to be abandoned before completion, according to a report released yesterday. The government-funded National Cancer Institute's clinical trials group isn't able to effectively study the benefits of new and current treatments, according to the analysis by the Institute of Medicine.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376119966 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QF0400X | Clinic/center - Federally Qualified Health Center (fqhc) | (* (Not Available)) | Primary |
News Archive
Ethicon Endo-Surgery, Inc. (EES), a Johnson & Johnson company, today announced it has received an irrevocable, unconditional offer from Devicor Medical Products (Devicor), a portfolio company of GTCR Golder Rauner, LLC, (GTCR), to acquire its Breast Care business. The EES Breast Care business sells products designed to help doctors diagnose breast cancer at early stages, while minimizing patient discomfort. Financial terms of the offer are not being disclosed.
The University of Florida will receive $29.5 million in federal stimulus funds over the next two years from the National Institute on Aging to begin a six-year study on whether a program of structured physical activity can prevent or delay major movement disability in older adults.
ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.
Bloomberg: "The government's cancer research network is 'approaching a state of crisis' as waste and inefficiency cause 40 percent of late-stage trials it funds to be abandoned before completion, according to a report released yesterday. The government-funded National Cancer Institute's clinical trials group isn't able to effectively study the benefits of new and current treatments, according to the analysis by the Institute of Medicine.
› Verified 1 days ago
Newbury Health Clinic Pllc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4628 Main Street, Newbury, VT 05051 Phone: 802-866-3000 Fax: 802-866-3012 |